Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Sodium:neurotransmitter symporter family protein | 0.0166 | 0.0237 | 0.0621 |
Echinococcus multilocularis | family S10 non peptidase ue (S10 family) | 0.0557 | 0.3328 | 0.8732 |
Trypanosoma brucei | serine peptidase, Clan SC, Family S10 | 0.0618 | 0.3811 | 0.5 |
Echinococcus granulosus | sodium and chloride dependent glycine | 0.0166 | 0.0237 | 0.0605 |
Echinococcus multilocularis | lysosomal protective protein | 0.0618 | 0.3811 | 1 |
Trypanosoma cruzi | serine peptidase, Clan SC, Family S10, putative | 0.0618 | 0.3811 | 0.5 |
Echinococcus granulosus | beta catenin | 0.0204 | 0.0535 | 0.1365 |
Echinococcus multilocularis | sodium and chloride dependent glycine | 0.0166 | 0.0237 | 0.0621 |
Trypanosoma brucei | serine peptidase, Clan SC, Family S10 | 0.0618 | 0.3811 | 0.5 |
Schistosoma mansoni | beta-catenin | 0.0204 | 0.0535 | 0.1403 |
Echinococcus granulosus | lysosomal protective protein | 0.0618 | 0.3811 | 0.9735 |
Loa Loa (eye worm) | Sodium:neurotransmitter symporter family protein | 0.0166 | 0.0237 | 0.0621 |
Schistosoma mansoni | sodium/chloride dependent transporter | 0.0166 | 0.0237 | 0.0621 |
Trypanosoma cruzi | serine peptidase, Clan SC, Family S10, putative | 0.0618 | 0.3811 | 0.5 |
Trypanosoma brucei | serine peptidase, Clan SC, Family S10 | 0.0618 | 0.3811 | 0.5 |
Mycobacterium tuberculosis | Probable glutamate racemase MurI | 0.1401 | 1 | 0.5 |
Onchocerca volvulus | Uncharacterized serine carboxypeptidase homolog | 0.0618 | 0.3811 | 1 |
Echinococcus granulosus | hypothetical protein | 0.0632 | 0.3915 | 1 |
Leishmania major | serine carboxypeptidase (CBP1), putative,serine peptidase, Clan SC, Family S10 | 0.0618 | 0.3811 | 0.5 |
Schistosoma mansoni | sodium/chloride dependent transporter | 0.0166 | 0.0237 | 0.0621 |
Trypanosoma cruzi | serine carboxypeptidase (CBP1), putative | 0.0618 | 0.3811 | 0.5 |
Brugia malayi | Serine carboxypeptidase F41C3.5 precursor | 0.0618 | 0.3811 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0618 | 0.3811 | 1 |
Echinococcus multilocularis | beta catenin | 0.0204 | 0.0535 | 0.1403 |
Schistosoma mansoni | family S10 non-peptidase homologue (S10 family) | 0.0618 | 0.3811 | 1 |
Echinococcus granulosus | sodium and chloride dependent glycine | 0.0166 | 0.0237 | 0.0605 |
Trypanosoma cruzi | serine carboxypeptidase (CBP1), putative | 0.0618 | 0.3811 | 0.5 |
Schistosoma mansoni | family S10 unassigned peptidase (S10 family) | 0.0618 | 0.3811 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0166 | 0.0237 | 0.0621 |
Mycobacterium ulcerans | glutamate racemase | 0.1401 | 1 | 1 |
Loa Loa (eye worm) | HMP-2 protein | 0.0204 | 0.0535 | 0.1403 |
Loa Loa (eye worm) | hypothetical protein | 0.0166 | 0.0237 | 0.0621 |
Echinococcus granulosus | family S10 non peptidase ue S10 family | 0.0557 | 0.3328 | 0.8501 |
Schistosoma mansoni | hypothetical protein | 0.0496 | 0.2847 | 0.747 |
Brugia malayi | Armadillo/beta-catenin-like repeat family protein | 0.0204 | 0.0535 | 0.1403 |
Echinococcus multilocularis | sodium and chloride dependent glycine | 0.0166 | 0.0237 | 0.0621 |
Treponema pallidum | glutamate racemase | 0.1401 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (ADMET) | = 89 % | Cytotoxicity against human FRT-Jurkat cells assessed as reduction of cell viability by measuring cleaved caspase 3 at 10 uM by flow cytometer | ChEMBL. | No reference |
Inhibition (binding) | = 36 % | Inhibition of NFkappaB in human FRT-Jurkat cells expressing GFP assessed as reduction of TNF expression at 10 uM after 24 hrs by flow cytometry relative to control | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.